跳至主要内容
临床试验/IRCT20140818018842N38
IRCT20140818018842N38招募中1 期

Investigating the safety and efficacy of active natural killer cell infusions in patients with MRD-positive Acute Lymphoblastic Leukemia after hematopoietic stem cell transplantation: a phase I/II trial

Tehran University of Medical Sciences0 个研究点目标入组 36 人开始时间: 待定最近更新:

试验速览

阶段
1 期
状态
招募中
入组人数
36

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 65 years(—)
性别
All

入选标准

  • Age 18 years old or more
  • Patients with B-ALL or T-ALL who are MRD positive after receiving therapy.

排除标准

  • Symptomatic coronary artery disease
  • Karnofsky Performance Score < 60
  • Patients with uncontrolled bacterial, viral or fungal infection
  • Acute graft versus host disease
  • Females who are pregnant or breastfeeding.

研究者

相似试验